Psoriatic arthritis

1. High-Yield Summary

Psoriatic arthritis (PsA) is a chronic, heterogeneous, seronegative inflammatory spondyloarthropathy that develops in approximately 20% to 30% of patients with cutaneous psoriasis, classically manifesting with peripheral arthritis, axial spondylitis, dactylitis, and enthesitis.

• Diagnostic Hallmark: Characterized by the absence of rheumatoid factor (RF) and anti-CCP antibodies, distal interphalangeal (DIP) joint involvement, nail dystrophies (pitting, onycholysis), and dactylitis (“sausage digit”).
• Pathognomonic Imaging: Radiographs display simultaneous bone erosion and bone proliferation (periostitis, “whiskering”, asymmetric syndesmophytes) without periarticular osteopenia, progressing in severe cases to “pencil-in-cup” deformities or arthritis mutilans.
• Validated Diagnostic Criteria: The CASPAR (Classification Criteria for Psoriatic Arthritis) criteria require established inflammatory musculoskeletal disease plus at least 3 points across cutaneous, ungueal, serologic, dactylitic, and radiographic categories (91.4% sensitivity, 98.7% specificity).
• Perioperative Mandate: In accordance with ACR/AAHKS guidelines, biologic DMARDs (TNFi, IL-17i, IL-23i) must be withheld for one dosing cycle prior to elective arthroplasty and restarted 14 days postoperatively after complete wound healing. Never place surgical incisions through active psoriatic plaques.

2. Anatomy

The primary anatomic target in psoriatic arthritis is the synovio-entheseal complex (SEC). Unlike rheumatoid arthritis, which originates as an autoimmune synovitis, psoriatic arthritis pathophysiology is centered at the enthesis where tendons, ligaments, and capsule insert into bone, secondarily transmitting inflammation to the adjacent synovial membrane.

Pertinent Functional Anatomy

• Digital Entheses: The extensor tendon terminal insertion into the distal phalanx base and the collateral ligaments of the distal interphalangeal (DIP) joint are intimately linked to the nail bed matrix. This microanatomical continuity explains the strong clinical association between nail dystrophy and DIP joint disease.
• Lower Extremity Entheses: Common sites of symptomatic enthesitis include the Achilles tendon insertion onto the calcaneus, the plantar fascia origin at the medial calcaneal tubercle, and the patellar tendon insertions at the inferior patellar pole and tibial tuberosity.
• Axial Skeletal Structures: Sacroiliac joints and discovertebral junctions. Entheseal stress at the outer fibers of the annulus fibrosus stimulates non-marginal, coarse syndesmophyte formation.

Neurovascular Danger Zones

• Digital Neurovascular Bundles: During surgical correction of chronic flexion contractures or arthrodesis of DIP/PIP joints, the proper palmar digital arteries and nerves can be foreshortened, tethered, or enveloped in proliferative fibrous tissue, posing an acute risk of digital ischemia upon joint extension.
• Posterior Tibial Neurovascular Bundle: In hindfoot and ankle reconstructions for severe enthesopathic collapse or subtalar joint destruction, the posterior tibial artery and tibial nerve are at risk behind the medial malleolus within the tarsal tunnel.
• Lateral Cutaneous Nerve of the Forearm and Radial Nerve: At risk during lateral approaches for elbow synovectomy or radiocapitellar reconstruction.

Surgical Internervous Planes

• Digit Approaches: Dorsal longitudinal or trans-tendinous extensor-splitting approaches to the PIP and DIP joints preserve lateral digital bundles.
• Hip Arthroplasty: The anterolateral (Watson-Jones) approach exploits the internervous interval between the superior gluteal nerve (gluteus medius) and the femoral nerve (tensor fasciae latae). The direct anterior approach exploits the intermuscular interval between tensor fasciae latae and sartorius.
• Knee Arthroplasty: Medial parapatellar or subvastus exposure through the quadriceps tendon and patellar retinaculum, with meticulous preservation of the infrapatellar branch of the saphenous nerve.

3. Pathogenesis

The pathogenesis of psoriatic arthritis represents an interplay of biomechanical stress, genetic predisposition (notably HLA-B27 and HLA-Cw6), and innate/adaptive immunologic dysregulation. Mechanical microdamage at the entheses acts as a trigger (“deep Koebner phenomenon”), initiating an inflammatory cascade governed by the IL-23/IL-17 cytokine axis.

Mechanosensitive tissue resident cells, including entheseal gamma-delta T cells, group 3 innate lymphoid cells (ILC3s), and macrophages, release high concentrations of interleukin-23 (IL-23), interleukin-17A/F (IL-17), tumor necrosis factor-alpha (TNF-alpha), and interleukin-22 (IL-22). This inflammatory milieu produces two simultaneous and diametrically opposed tissue responses:

• Osteoclastic Osteolysis: Mediated by TNF-alpha and receptor activator of nuclear factor-kappa B ligand (RANKL), leading to subchondral bone erosions, joint space narrowing, and articular resorption.
• Osteoblastic Bone Proliferation: Mediated by IL-22, IL-17, and the bone morphogenetic protein (BMP) / Wnt signaling pathways, stimulating periosteal bone formation, enthesophytes, and syndesmophytes. This dual process of erosion and productive new bone formation represents the hallmark pathologic signature that distinguishes psoriatic arthritis from rheumatoid arthritis.

4. Natural History

PsA affects 0.1% to 1% of the general population and develops in 20% to 30% of individuals with plaque psoriasis. The mean age of disease onset is between 30 and 55 years, with an equal male-to-female ratio, although axial spondylitis is more frequent in men.

In roughly 75% of patients, cutaneous psoriasis precedes articular manifestations by a median of 7 to 10 years; in 15%, arthritis and skin lesions appear simultaneously, and in 10%, joint symptoms precede cutaneous disease (psoriatic arthritis sine psoriasis). If untreated, up to 50% of patients develop progressive erosive disease within two years of onset, leading to joint subluxation, ankylosis, and severe physical disability. Less than 5% progress to arthritis mutilans, characterized by catastrophic osteolysis of the phalanges and metacarpals.

Psoriatic arthritis is also associated with significant systemic co-morbidities, including metabolic syndrome, non-alcoholic fatty liver disease, accelerated atherosclerosis, and increased cardiovascular mortality, emphasizing the need for comprehensive systemic disease control.

5. Clinical Presentation

History

Patients report inflammatory musculoskeletal pain characterized by prolonged morning stiffness lasting greater than 30 to 60 minutes, which improves with physical activity and worsens with prolonged rest. Key historical features include:

• Cutaneous and Family History: Personal history of scalp, extensor surface, or intergluteal/umbilical psoriasis, or a first-degree relative with diagnosed psoriasis.
• Enthesitic Symptoms: Unilateral or bilateral heel pain (Achilles tendon or plantar fascia insertion), pain at the patellar tendon, or lateral epicondylar tenderness without repetitive occupational trauma.
• Inflammatory Back Pain: Alternating buttock pain, insidious onset of lower back stiffness prior to age 40, night pain waking the patient in the second half of the night.

Physical Examination

Physical examination must systematically assess peripheral joints, the axial spine, entheseal points, and cutaneous/nail integument:

6. Imaging and Diagnostic Studies

Plain Radiography (Gold Standard Initial Modality)

Bilateral plain radiographs of hands, wrists, feet, and symptomatic axial/peripheral joints represent the gold standard initial evaluation. Characteristic findings include:

• Combination of Erosion and Proliferation: Marginal erosions accompanied by adjacent fluffy periosteal new bone formation (“whiskering”) along the shaft and metaphysis.
• Absence of Periarticular Osteopenia: Normal bone mineralization adjacent to severely eroded joints, contrasting sharply with the profound juxta-articular osteopenia of rheumatoid arthritis.
• “Pencil-in-Cup” Deformity: Severe marginal erosion and tapering of the proximal phalanx or metatarsal head (“pencil”) fitting into the widened, excavated base of the adjacent phalanx (“cup”), classic for advanced DIP/PIP disease.
• Acro-osteolysis: Resorption of the distal tufts of the terminal phalanges.
• Axial Radiographs: Asymmetric sacroiliitis (Grade II-IV) and coarse, bulky, non-marginal syndesmophytes that originate away from the discovertebral margins, distinct from the delicate, symmetric syndesmophytes of ankylosing spondylitis.

Advanced Imaging Modalities

• Magnetic Resonance Imaging (MRI): High sensitivity for early pathology. Demonstrates enthesitis, bone marrow edema (osteitis), tenosynovitis, and subtle sacroiliac inflammation prior to plain radiographic changes. T1 fat-suppressed post-gadolinium or STIR sequences highlight active soft-tissue inflammation.
• High-Resolution Ultrasound with Power Doppler: Cost-effective chairside modality. Power Doppler signaling detects active vascularization at enthesopathic insertions (Achilles, plantar fascia), digital flexor tenosynovitis, and subclinical joint synovitis.

Laboratory Investigations

• Serology: Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies are negative (positive in < 5% of patients at low titers).
• Inflammatory Markers: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are elevated in 50% to 60% of patients with active polyarticular disease, but normal levels do not exclude active monoarticular or entheseal PsA.
• Human Leukocyte Antigen: HLA-B27 is positive in 50% to 70% of axial psoriatic spondylitis cases (compared to 15% to 20% in isolated peripheral PsA).
• Arthrocentesis: Demonstrates an inflammatory synovial fluid profile (leukocyte count typically 5,000 to 50,000/mcL with >50% polymorphonuclear cells), sterile culture, and absence of monosodium urate or calcium pyrophosphate crystals.

7. Classification

Modern clinical practice and clinical trials utilize the validated CASPAR (Classification Criteria for Psoriatic Arthritis) criteria to establish the diagnosis with high sensitivity and specificity.

Diagnostic Threshold: A patient with established inflammatory musculoskeletal disease (joint, spine, or entheseal) who scores >= 3 points is classified as having psoriatic arthritis (91.4% sensitivity, 98.7% specificity).

Historically and clinically, the disease is also categorized according to the classic Moll and Wright Subtypes (1973):

8. Treatment

Medical & Pharmacologic Management

Medical management follows a stepped, treat-to-target algorithm in collaboration with rheumatology, guided by EULAR and GRAPPA consensus recommendations:

• First-Line Conservative Therapy: Non-steroidal anti-inflammatory drugs (NSAIDs) and physical therapy for mild oligoarticular or entheseal disease. Intra-articular corticosteroid injections provide rapid relief for localized peripheral mono/oligoarthritis flares.
• Conventional Synthetic DMARDs (csDMARDs): Methotrexate (15 to 25 mg weekly) is the first-line systemic agent for active peripheral arthritis. Alternative csDMARDs include sulfasalazine and leflunomide. csDMARDs have no proven efficacy for axial disease.
• Biologic DMARDs (bDMARDs): Indicated upon csDMARD failure or as first-line therapy for severe axial disease, extensive dactylitis, or destructive peripheral arthritis. Classes include:
  • TNF-alpha Inhibitors: Adalimumab, etanercept, infliximab, golimumab, certolizumab pegol. Highly effective across peripheral, axial, and entheseal domains.
  • IL-17 Inhibitors: Secukinumab, ixekizumab, and bimekizumab (dual IL-17A/F inhibitor). Demonstrates superior cutaneous clearance and robust musculoskeletal efficacy.
  • IL-23 Inhibitors: Guselkumab, risankizumab, ustekinumab (IL-12/23). Exceptional skin and entheseal clearance.
• Targeted Synthetic DMARDs (tsDMARDs): Janus kinase (JAK) inhibitors (tofacitinib, upadacitinib) and phosphodiesterase-4 (PDE4) inhibitors (apremilast) provide oral alternatives for patients with inadequate response or contraindications to biologics.

Perioperative Medication Protocol (ACR/AAHKS Guidelines)

To balance the competing risks of postoperative prosthetic joint infection (PJI) against inflammatory disease flare:

• Methotrexate: Continue uninterrupted through the perioperative period for elective arthroplasty (provided renal and hepatic function are normal).
• Biologic Agents (bDMARDs): Withhold for one full dosing cycle prior to surgery. For example, a bi-weekly biologic (e.g., adalimumab) should be administered 3 to 4 weeks before surgery, scheduling surgery during the week following the omitted dose.
• Postoperative Resumption: Biologics are resumed at a minimum of 14 days postoperatively, strictly conditional upon primary wound healing, suture/staple removal, and absence of local or systemic infectious symptoms.
• Cutaneous Plaque Rule: Absolute contraindication to making surgical incisions directly through active, erythematous, scaling psoriatic plaques due to dense colonization with Staphylococcus aureus. Preoperative clearance using high-potency topical corticosteroids or targeted phototherapy is mandatory.

Operative Interventions

The primary goals of orthopaedic surgery in psoriatic arthritis are intractable pain relief, correction of disabling joint deformities, restoration of functional stability, and eradication of end-stage joint destruction:

• Hand and Wrist Reconstruction:
  • Arthrodesis: DIP joint arthrodesis in 5 to 10 degrees of flexion using headless compression screws or crossed K-wires provides reliable pain relief and pinch stability. PIP joint fusion is favored for radial digits (index/middle).
  • Arthroplasty: Silicone or surface replacement arthroplasty for MCP joints and ulnar PIP joints (ring/small) in low-demand patients to preserve grip.
  • Synovectomy & Tenosynovectomy: Open or arthroscopic extensor/flexor tenosynovectomy for proliferative tenosynovitis resistant to 6 months of biologic therapy to prevent spontaneous tendon rupture.
• Foot and Ankle Surgery: First metatarsophalangeal (MTP) joint arthrodesis combined with lesser metatarsal head resection arthroplasty (Hoffmann-Clayton procedure) for severe forefoot subluxation and painful plantar callosities. Subtalar or triple arthrodesis for hindfoot destruction.
• Total Joint Arthroplasty (TJA):
  • Total Hip Arthroplasty (THA): Uncemented femoral and acetabular components are favored given favorable biologic bone ingrowth, though meticulous bone bed preparation is essential due to variable bone density.
  • Total Knee Arthroplasty (TKA): Posterior-stabilized or constrained condylar designs are frequently required when collateral ligament competency is compromised by long-standing asymmetric synovio-entheseal destruction.

Indications & Contraindications

• Indications: End-stage joint destruction with intractable pain refractory to comprehensive biologic therapy; severe mechanical instability or fixed deformity impairing activities of daily living; acute or impending tendon rupture; progressive compressive neuropathy (e.g., severe carpal tunnel syndrome secondary to proliferative tenosynovitis).
• Contraindications: Active superficial or deep skin infection; incision planned through an active psoriatic plaque; medically uncontrolled systemic inflammation; severe peripheral vascular disease; non-compliance with perioperative immunosuppressive holding protocols.

9. Outcome

Modern multimodal therapy combining targeted biologics and timely surgical intervention has transformed outcomes in psoriatic arthritis:

• Total Hip and Knee Arthroplasty: 10- to 15-year implant survivorship in psoriatic arthritis ranges from 88% to 94%, comparable to rheumatoid arthritis cohorts. Patients achieve marked improvements in validated patient-reported outcome measures (PROMs), including the Hip Disability and Osteoarthritis Outcome Score (HOOS), Knee Injury and Osteoarthritis Outcome Score (KOOS), and Short Form-36 (SF-36) physical components.
• Hand and Wrist Arthrodesis: Primary fusion rates exceed 90% for DIP and PIP arthrodesis, restoring stable, pain-free key and tip pinch. Reoperation rates for nonunion or hardware irritation remain under 8%.
• Systemic Medical Outcomes: Biologic therapy targeting TNF and the IL-17/IL-23 axis produces ACR50 response rates in 40% to 60% of patients and halts progressive radiographic joint destruction in over 80% of treated cohorts.

10. Complications

11. Pearls and Pitfalls

• Incisional Clearance Pearl: Never make a surgical skin incision through an active psoriatic plaque. Psoriatic plaques harbor heavy colonies of Staphylococcus aureus and streptococci within cracked epidermis. Treat the skin site vigorously with high-potency topical steroids or calcipotriene for 4 to 6 weeks before elective surgery until complete re-epithelialization is achieved.
• The Diagnostic “Hidden Psoriasis” Pearl: When evaluating a patient with seronegative inflammatory oligoarthritis or asymmetric DIP swelling, meticulously inspect the scalp, external auditory canals, postauricular sulci, umbilicus, and natal cleft. Mild, unrecognized cutaneous psoriasis is often concealed in these areas.
• Diagnostic Gout Pitfall: Avoid confusing psoriatic dactylitis with acute gout. Patients with extensive psoriasis frequently have secondary hyperuricemia due to accelerated epidermal cell turnover, and acute dactylitis can mimic acute podagra. Perform arthrocentesis or polarising microscopy to definitively rule out uric acid crystals.
• Rheumatoid Factor Seronegative Pitfall: Do not misdiagnose symmetric polyarticular PsA as seronegative rheumatoid arthritis. Look specifically for absence of periarticular osteopenia, presence of DIP involvement, nail pitting, and asymmetric syndesmophytes on pelvic/spinal radiographs.
• Heterotopic Ossification Awareness: Because psoriatic arthritis is fundamentally an osteoproliferative spondyloarthropathy, patients undergoing total hip arthroplasty are at elevated risk for Brooker Class III/IV heterotopic ossification. Consider routine multimodal prophylaxis with oral NSAIDs (indomethacin) or radiation therapy in patients with prior axial ankylosis.

12. Controversy

Treat-to-Target (T2T) vs. Routine Symptom-Driven Care

While the Tight Control of Psoriatic Arthritis (TICOPA) trial demonstrated that a structured treat-to-target strategy aiming for Minimal Disease Activity (MDA) achieves superior clinical and radiographic outcomes compared to standard care, controversy persists regarding drug toxicity, healthcare costs, and patient adherence in real-world cohorts where frequent therapy escalations are mandated.

First-Line Biologic Selection: TNF vs. IL-17 vs. IL-23 Inhibition

Debate continues regarding the optimal first-line biologic mechanism in patients presenting with concurrent high-burden cutaneous psoriasis and destructive peripheral arthritis. Head-to-head trials demonstrate that IL-17 and IL-23 inhibitors achieve higher rates of complete skin clearance (PASI90/100) compared to classic TNF inhibitors, but whether they confer superior long-term joint preservation and lower perioperative infection rates in orthopaedic surgical candidates remains an active area of investigation.

Elective Arthroplasty Through Inactive Psoriatic Skin

While operating through active, flaking plaques is uniformly condemned, controversy remains regarding surgical timing in patients with extensive plaque coverage where completely plaque-free incision lines cannot be achieved. Emerging consensus suggests that stable, non-erythematous, well-moisturized skin with negative preoperative skin swabs can be safely utilized when combined with chlorhexidine-alcohol skin preparation and targeted perioperative antibiotic coverage.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Mease PJ, Gladman DD, Merola JF et al. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2024. doi:10.1093/rheumatology/kead705 [Level I: Systematic Review & Network Meta-Analysis]
• Wu S, Xu Y, Yang L et al. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Front Immunol. 2023. doi:10.3389/fimmu.2023.1294416 [Level I: Systematic Review & Meta-Analysis]
• Alinaghi F, Calov M, Kristensen LE et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019. doi:10.1016/j.jaad.2018.06.027 [Level I: Systematic Review & Meta-Analysis]
• Taylor W, Gladman D, Helliwell P et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006. doi:10.1002/art.21972 [Level II: Multicenter Prospective Diagnostic Validation Cohort]
• Gossec L, Baraliakos X, Kerschbaumer A et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020. doi:10.1136/annrheumdis-2020-217159 [Level V: Clinical Practice Consensus Guideline]
• Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973. doi:10.1016/0049-0172(73)90035-8 [Level V: Seminal Conceptual Classification & Clinical Series]

15. Master Class Pro-Tip

When planning elective joint replacement or small joint arthrodesis in psoriatic arthritis, surgical success hinges on three non-negotiable principles: First, execute an uncompromising preoperative dermatologic clearance protocol—never rush a patient with erythematous, desquamating plaques into the operating suite, as bacterial colonization within fissured skin dramatically escalates prosthetic joint infection risks. Second, coordinate directly with the treating rheumatologist to execute the ACR/AAHKS biologic withholding window (exactly one dosing interval prior to surgery, resuming at 14 days post-op only after complete, dry wound re-epithelialization). Third, anticipate abnormal bone morphology: unlike rheumatoid arthritis where osteopenic soft bone predominates, psoriatic bone presents an erratic combination of subchondral osteolysis and dense, sclerotic periosteal hyperostosis. Prepare both high-speed burrs for meticulous bone sculpting and structural augmentations or cerclage cables to address intraoperative cortical fragility.

Master Class Surgical Pearl: Perioperative Strategy and Structural Reconstruction in Psoriatic Arthritis